Brent Page, University of British Columbia

Research

Drug Discovery Medicinal Chemistry Alzheimer'S Disease Neuroinflammation Nudix Hydrolase Nudt5 Chemical Biology Drug Repurposing

Latest papers

Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update.
Expert opinion on therapeutic patents · 2023
Chemically engineering the drug release rate of a PEG-paclitaxel conjugate using click and steric hindrance chemistries for optimal efficacy.
Biomaterials · 2022
To inhibit TrxR1 is to inactivate STAT3-Inhibition of TrxR1 enzymatic function by STAT3 small molecule inhibitors.
Redox biology · 2020

All 3 publications

Latest funding

Developing fenoxacrim derivatives against drug resistant Mycobacterium tuberculosis
CIHR · 2026 · Co-investigator
$963,900
Novel therapeutics for neurodegeneration - Targeting NUDT5 in Alzheimer's Disease
CIHR · 2025 · Nominated PI
$1,273,725
Novel therapeutics for neurodegeneration - Targeting NUDT5 in Alzheimer's Disease
CIHR · 2025 · Nominated PI
$50,000

All 9 grants and awards

3 publications.

01

Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update.

Jaworski C, Iliev P, Wängler C, Wängler B, Page B, Schirrmacher R, Bailey JJ

Expert opinion on therapeutic patents2023

DOI: 10.1080/13543776.2023.2262136 PMID: 37735897

02

Chemically engineering the drug release rate of a PEG-paclitaxel conjugate using click and steric hindrance chemistries for optimal efficacy.

Nguyen A, Chao PH, Ong CY, Rouhollahi E, Fayez NA, Lin L, Brown JI, Böttger R, Page B, Wong H, Li SD

Biomaterials2022

DOI: 10.1016/j.biomaterials.2022.121735 PMID: 36055815

03

To inhibit TrxR1 is to inactivate STAT3-Inhibition of TrxR1 enzymatic function by STAT3 small molecule inhibitors.

Busker S, Page B, Arnér ESJ

Redox biology2020

DOI: 10.1016/j.redox.2020.101646 PMID: 32863208

Developing fenoxacrim derivatives against drug resistant Mycobacterium tuberculosis

Co-investigatorCIHR2026Project Grant

Principal investigators: Av-Gay, Yossef

Keywords: Antibiotics; Drug Discovery; Hit To Lead; Medicinal Chemistry; Sar; Tuberculosis

$963,900

Novel therapeutics for neurodegeneration - Targeting NUDT5 in Alzheimer's Disease

Nominated PICIHR2025Project Grant

Principal investigators: Page, Brent

Keywords: Alzheimer'S Disease; Drug Discovery; Medicinal Chemistry; Neuroinflammation; Nudix Hydrolase; Nudt5

$1,273,725

Novel therapeutics for neurodegeneration - Targeting NUDT5 in Alzheimer's Disease

Nominated PICIHR2025Project Grant - PA: Early Career Investigator Prize in Research in Aging

Principal investigators: Page, Brent

Keywords: Alzheimer'S Disease; Drug Discovery; Medicinal Chemistry; Neuroinflammation; Nudix Hydrolase; Nudt5

$50,000

Repurposing Histamine Receptor 1 (HR1) blockers for host directed therapy of tuberculosis

SupervisorCIHR2023CIHR REDI Early Career Transition Award - Pandemic Prepared./Health Emergencies

Principal investigators: Sahile, Henok A

Keywords: Antihistamine Drugs; Drug Discovery; Drug Repurposing; Host Directed Therapy; Medicinal Chemistry; Tuberculosis

$270,000

Exploiting protein stability changes to identify next generation chemical probes and target engagement technologies

Principal investigatorNSERC2022Discovery Grants Program - Individual

Principal investigators: Page, Brent

$111,000

Exploiting protein stability changes to identify next generation chemical probes and target engagement technologies

Principal investigatorNSERC2022Discovery Launch Supplement

Principal investigators: Page, Brent

$12,500

Overcoming Dihydrofolate Reductase Inhibitor Resistance Using Pyrimethamine-inspired Proteolysis Targeting Chimeras

Nominated PICIHR2021Project Grant

Principal investigators: Page, Brent

Keywords: Chemical Biology; Drug Discovery; Drug Repurposing; Drug Resistance; Medicinal Chemistry; Proteolysis Targeting Chimeras (Protacs); Target Engagement Assays

$812,814

Biomolecular Imaging System for Nanomedicine and Chemical Biology Applications in Pharmaceutical Sciences

Co-investigatorNSERC2021Research Tools and Instruments

Principal investigators: Frankel, Adam

$144,803

Targeting TSLP - Novel anti-inflammatory compounds for the treatment and prevention of atopic diseases

Co-investigatorCIHR2020Project Grant

Principal investigators: Hedtrich, Sarah

Keywords: Atopic Diseases; Drug Discovery And Development; Inflammatory Skin Diseases; New Anti-Inflammatory Drugs; Topical Drug Delivery; Tslp Inhibitors

$803,250

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Shyh-Dar Li

Faculty

1 shared papers, latest 2022

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2025

Subject: Prospective PhD student: Drug Discovery Dear Professor Page, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update." (2023), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Novel therapeutics for neurodegeneration - Targeting NUDT5 in Alzheimer's Disease" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]